1-Methyl-3-propyl-4-(p-chlorophenyl)piperidine
Chemical compound
From Wikipedia, the free encyclopedia
1-Methyl-3-propyl-4-(p-chlorophenyl)piperidine is a drug developed by a team led by Alan Kozikowski, which acts as a potent dopamine reuptake inhibitor, and was developed as a potential therapeutic agent for the treatment of cocaine addiction.[1] As with related compounds such as nocaine, it is a structurally simplified derivative of related phenyltropane compounds.[2] Its activity at the serotonin and noradrenaline transporters has not been published, though most related 4-phenylpiperidine derivatives are relatively selective for inhibiting dopamine reuptake over the other monoamine neurotransmitters. While several of its isomers are active, the (3S,4S)-enantiomer is by far the most potent.[3][4] The rearranged structural isomer 2-[1-(4-chlorophenyl)butyl]piperidine is also a potent inhibitor of dopamine reuptake.[5]

2-[1-(4-chlorophenyl)butyl]piperidine[6]
- 214335-23-6 (3S,4S enantiomer)
1956381-81-9 (racemate)
| Identifiers | |
|---|---|
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C15H22ClN |
| Molar mass | 251.80 g·molâ1 |
| 3D model (JSmol) | |
| |
| |
